- Home
- REGN vs JCI Comparison
REGN vs JCI Comparison
Compare REGN & JCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- JCI
- Stock Information
- Founded
- REGN 1988
- JCI 1885
- Country
- REGN United States
- JCI Ireland
- Employees
- REGN N/A
- JCI N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- JCI Industrial Machinery/Components
- Sector
- REGN Health Care
- JCI Industrials
- Exchange
- REGN Nasdaq
- JCI Nasdaq
- Market Cap
- REGN 59.5B
- JCI 67.7B
- IPO Year
- REGN 1991
- JCI N/A
- Fundamental
- Price
- REGN $568.20
- JCI $107.82
- Analyst Decision
- REGN Buy
- JCI Buy
- Analyst Count
- REGN 23
- JCI 15
- Target Price
- REGN $794.83
- JCI $108.50
- AVG Volume (30 Days)
- REGN 991.3K
- JCI 4.5M
- Earning Date
- REGN 10-30-2025
- JCI 11-05-2025
- Dividend Yield
- REGN 0.62%
- JCI 1.37%
- EPS Growth
- REGN 5.03
- JCI 41.76
- EPS
- REGN 39.67
- JCI 3.37
- Revenue
- REGN $14,214,200,000.00
- JCI $23,402,000,000.00
- Revenue This Year
- REGN N/A
- JCI $3.22
- Revenue Next Year
- REGN $4.97
- JCI $5.35
- P/E Ratio
- REGN $14.32
- JCI $32.01
- Revenue Growth
- REGN 5.38
- JCI 22.22
- 52 Week Low
- REGN $476.49
- JCI $68.03
- 52 Week High
- REGN $1,170.58
- JCI $112.63
- Technical
- Relative Strength Index (RSI)
- REGN 50.07
- JCI 54.37
- Support Level
- REGN $552.98
- JCI $104.52
- Resistance Level
- REGN $588.70
- JCI $109.98
- Average True Range (ATR)
- REGN 16.19
- JCI 2.39
- MACD
- REGN -3.04
- JCI 0.07
- Stochastic Oscillator
- REGN 26.70
- JCI 61.26
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About JCI Johnson Controls International plc
Johnson Controls manufactures, installs, and services commercial HVAC systems, building management platforms and controls, fire and security solutions, and industrial refrigeration units. Commercial HVAC and fire and security each account for approximately 45% of sales, while industrial refrigeration and other solutions account for the remaining 10% of revenue. In fiscal 2024, Johnson Controls generated nearly $23 billion in pro forma revenue.